Format

Send to

Choose Destination
Surg Oncol. 2015 Sep;24(3):270-5. doi: 10.1016/j.suronc.2015.06.008. Epub 2015 Jun 12.

Is radioembolization ((90)Y) better than doxorubicin drug eluting beads (DEBDOX) for hepatocellular carcinoma with portal vein thrombosis? A retrospective analysis.

Author information

1
Department of Radiology, University of Louisville, United States. Electronic address: okakin01@louisville.edu.
2
University of Louisville Medical School, United States. Electronic address: d0kim016@louisville.edu.
3
University of Louisville Medical School, United States. Electronic address: jacob.edwards@louisville.edu.
4
Department of Surgical Oncology, University of Louisville, United States. Electronic address: Russell.brown@infirmaryhealth.org.
5
Department of Surgical Oncology, University of Louisville, United States. Electronic address: prejesh.philips@louisville.edu.
6
Department of Surgical Oncology, University of Louisville, United States. Electronic address: charles.scoggins@louisville.edu.
7
Department of Surgical Oncology, University of Louisville, United States. Electronic address: Robert.Martin@louisville.edu.

Abstract

INTRODUCTION:

This study compares radioembolization ((90)Y) versus doxorubicin drug eluting beads (DEBDOX) in the treatment of unresectable hepatocellular carcinoma with portal vein thrombosis.

METHODS:

Using our prospectively maintained, multi-center, non-controlled intra-arterial therapy registry, we identified 28 consecutive patients with hepatocellular carcinoma (HCC) and portal vein thrombosis (PVT) treated with DEBDOX and 20 with (90)Y. Follow-up protocol consisted of a 3-phase CT scan of the liver within 3 months post-treatment. Tumor response rates were measured according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria.

RESULTS:

There were 65 and 29 treatments in the DEBDOX and (90)Y groups respectively. Median age of DEBDOX was 59.8 (35-81) and (90)Y was 66.5 (49-82) years. A defined number of lesions were seen in 78% DEBDOX and 50% (90)Y patients. Patients were similar in the remaining 8 baseline characteristics including performance status, Child Pugh and extent of PVT. There were fewer overall side effects in the DEBDOX group compared to the (90)Y group (11% vs 39%; P = 0.03). There was better disease control (mRECIST) in the DEBDOX group compared to the (90)Y group (67% vs 20%; P = 0.0014). Median survival times were 10 months in DEBDOX and 3 months in the (90)Y group respectively from first treatment (log-rank, P = 0.037).

CONCLUSION:

DEBDOX is safe for patients with HCC and PVT and may have lower toxicity than (90)Y. It may also provide better disease control and survival benefit. Further studies are warranted to validate our observations and to determine if current clinical practice should be altered.

KEYWORDS:

Comparative; DEBTACE; Efficacy; RECIST; Toxicity

PMID:
26133576
DOI:
10.1016/j.suronc.2015.06.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center